Journal: Neuroscience Bulletin

Article Title: Anti-Hypertensive Action of Fenofibrate via UCP2 Upregulation Mediated by PPAR Activation in Baroreflex Afferent Pathway

doi: 10.1007/s12264-018-0271-1

Figure Lengend Snippet: Ultrasound parameters of cardiac performance in control and fructose-fed hypertensive (HFD-HTN) rats before and after treatment with fenofibrate (FF).

Article Snippet: Chronic Fenofibrate Treatment Scheme HFD and Ctrl rats were fed a diet containing fenofibrate (100 mg/kg per day) [ 31 , 32 ] (Sigma, St. Louis, MO) for 4 weeks (HFD + FF-4w, and Ctrl + FF-4w).

Techniques:

Journal: Neuroscience Bulletin

Article Title: Anti-Hypertensive Action of Fenofibrate via UCP2 Upregulation Mediated by PPAR Activation in Baroreflex Afferent Pathway

doi: 10.1007/s12264-018-0271-1

Figure Lengend Snippet: . A SBP of control and HFD rats with fenofibrate treatment for 4 weeks (4w), n = 8 rats/group. B–C MAP (mmHg) and heart rate (HR) baselines. D–E BRS (bpm/mmHg) induced by PE or SNP-1/3/10 (phenylephrine or sodium nitroprusside at 1, 3, and 10 μg/kg). n = 6–8 rats/group in B–E. Results were analyzed using two-way ANOVA followed by Bonferroni’s post hoc test and averaged data are presented as mean ± SD. *P < 0.05, **P < 0.01 vs Ctrl; #P < 0.05, ##P < 0.01 vs HFD.

Article Snippet: Chronic Fenofibrate Treatment Scheme HFD and Ctrl rats were fed a diet containing fenofibrate (100 mg/kg per day) [ 31 , 32 ] (Sigma, St. Louis, MO) for 4 weeks (HFD + FF-4w, and Ctrl + FF-4w).

Techniques:

Journal: Neuroscience Bulletin

Article Title: Anti-Hypertensive Action of Fenofibrate via UCP2 Upregulation Mediated by PPAR Activation in Baroreflex Afferent Pathway

doi: 10.1007/s12264-018-0271-1

Figure Lengend Snippet: Cardiac parameters in HFD and fenofibrate-treated rats. A Images representing the cardiac morphology of Ctrl, Ctrl + FF (4w), HFD, and HFD + FF (4w) rats in the SAX model. B Diastolic LVID (LVIDd, mm; n = 5/group). Results were analyzed using two-tailed unpaired Student’s t-test and averaged data are presented as mean ± SD; *P < 0.05 vs Ctrl, #P < 0.05 vs HFD.

Article Snippet: Chronic Fenofibrate Treatment Scheme HFD and Ctrl rats were fed a diet containing fenofibrate (100 mg/kg per day) [ 31 , 32 ] (Sigma, St. Louis, MO) for 4 weeks (HFD + FF-4w, and Ctrl + FF-4w).

Techniques: Two Tailed Test

Journal: Neuroscience Bulletin

Article Title: Anti-Hypertensive Action of Fenofibrate via UCP2 Upregulation Mediated by PPAR Activation in Baroreflex Afferent Pathway

doi: 10.1007/s12264-018-0271-1

Figure Lengend Snippet: Upregulation of UCP2 at the protein level in the NTS and NG of HFD rats after chronic fenofibrate treatment. A, B Protein expression of UCP2 in the NG tissues of HFD and HFD + FF-4w rats (n = 5 duplications from 10 rats/group). C, D Protein expression of UCP2 in the NTS tissues of HFD and HFD + FF-4w rats (n = 6 duplications from 24 rats/group). E Superoxide dismutase (SOD) levels in the NTS (n = 4/group). F Superoxide (SO) levels in the NTS (n = 4/group). Results were analyzed using two-tailed unpaired Student’s t-test, and averaged data are presented as mean ± SD. *P < 0.05 vs HFD, **P < 0.01 vs Ctrl, ##P < 0.01 vs HFD. The gels were run under the same experimental conditions.

Article Snippet: Chronic Fenofibrate Treatment Scheme HFD and Ctrl rats were fed a diet containing fenofibrate (100 mg/kg per day) [ 31 , 32 ] (Sigma, St. Louis, MO) for 4 weeks (HFD + FF-4w, and Ctrl + FF-4w).

Techniques: Expressing, Two Tailed Test

Journal: Neuroscience Bulletin

Article Title: Anti-Hypertensive Action of Fenofibrate via UCP2 Upregulation Mediated by PPAR Activation in Baroreflex Afferent Pathway

doi: 10.1007/s12264-018-0271-1

Figure Lengend Snippet: Schematic of the working hypothesis. Interaction of PPARα/γ with fibroblast growth factor 21 (FGF21) was shown to regulate the blood pressure of HFD rats by modulating baroreflex afferent function in a previous study [10]. In the current working model, fenofibrate (as a PPAR-α agonist) up-regulates PPAR-α and PPAR-γ (synergistically with PPAR-α) and directly contributes to the up-regulation of UCP2 and improvement of oxidative stress via the baroreflex afferent pathway in the HFD model.

Article Snippet: Chronic Fenofibrate Treatment Scheme HFD and Ctrl rats were fed a diet containing fenofibrate (100 mg/kg per day) [ 31 , 32 ] (Sigma, St. Louis, MO) for 4 weeks (HFD + FF-4w, and Ctrl + FF-4w).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Alphataxin, an Orally Available Small Molecule, Decreases LDL Levels in Mice as a Surrogate for the LDL-Lowering Activity of Alpha-1 Antitrypsin in Humans

doi: 10.3389/fphar.2021.695971

Figure Lengend Snippet: All 5 Classes of β-Lactams Bind to HLE-G and HLE-CS.

Article Snippet: The following representatives of the five classes of β-lactams were screened for activity: I Cephalosporins (Cephems) 1) Cephalexin (CAS# 15686-71-2, 347.4 mw) (Cayman Chemical 9002009, batch 0462553-11) 2) Cefuroxime (CAS# 55268-75-2, 424.39 mw) (SigmaAldrich 34218-100 mg, batch SZBE050XV) II Penicillins (Penams) 1) D-Ampicillin (CAS# 63-53-4, 349.4 mw) (SigmaAldrich A9393-5 g, batch 086M4774V) 2) Penicillin V (CAS# 87-08-1, 350.39 mw) (SigmaAldrich 1504489-200 mg, batch R05030) 3) Dicloxacillin (CAS# 3116-76-5, 492.31 mw) (SigmaAldrich 46182-100 mg, batch SZBD263XV) 4) Amoxicillin (CAS# 34642-77-8, 365.40 mw) (SigmaAldrich A8523-1G, batch 066M4760V) 5) Alphataxin (CAS#19379-33-0, 349.4 mw) (BOC Sciences, batch B17LM02161) III Monobactams 1) Aztreonam (CAS# 78110-38-0, 435.43 mw) (SigmaAldrich A6848-50 mg, batch MKBW2997V) 2) Ezetimibe (CAS# 163222-33-1, 409.43 mw) (SigmaAldrich 1269028-250 mg, batch F028D0) IV Penems 1) Faropenem (CAS# 122547-49-3, 307.30 mw) (SigmaAldrich F8182-10 mg, batch 0000016430) V Carbapenems 1) Doripenem (CAS# 148016-81-3, 420.50 mw) (SigmaAldrich 32138-25 mg, batch BCBR7602V) Antibiotic activity .

Techniques: Concentration Assay

Journal: Frontiers in Medicine

Article Title: Maternal, newborn and breast milk concentrations of elexacaftor/tezacaftor/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy

doi: 10.3389/fmed.2023.1274303

Figure Lengend Snippet: LC–MS/MS method development for measuring ETI in biological samples. (A,B) HPLC chromatograms of VX-445, VX-661, and VX-770 spiked (0.05 ng/μL) in pooled blank human plasma or breastmilk. Proteins were removed by precipitation and samples injected (10 μL) into the C18-HPLC system. (C–E) Full product ion scan plots of VX-455, VX-661, and VX-770 obtained with MS/MS. Main transitions for each target molecules are in red. Bond cleavage sites are represented by dashed lines. Data are representative from n = 20 LC–MS/MS separate injections.

Article Snippet: At the age of 31, she was prescribed ETI (Elexacaftor 100 mg/die, Tezacaftor, 50 mg/die, Ivacaftor 75 mg/die) in combination with Ivacaftor (150 mg/die) as standard of care (Kaftrio + Kalydeco, Vertex Pharmaceuticals) in association with flunisolide (Fluspiral) 125 μg 1 puff × 2/day and salbutamol 3 puff × 2/day.

Techniques: Liquid Chromatography with Mass Spectroscopy, Clinical Proteomics, Injection, Tandem Mass Spectroscopy

Journal: Frontiers in Medicine

Article Title: Maternal, newborn and breast milk concentrations of elexacaftor/tezacaftor/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy

doi: 10.3389/fmed.2023.1274303

Figure Lengend Snippet: Mean calibration curves of ETI in human plasma and breast milk. Eight-point calibration curves were obtained for each an-analyte with a pool of blank plasma and/ milk spiked with 0.39–50 pg./μL of working solutions of VX-445, VX-661, and VX-770. Relative responses were calculated as ratio between area of the standard ( n = 5 replicate/concentration) over that of IS.

Article Snippet: At the age of 31, she was prescribed ETI (Elexacaftor 100 mg/die, Tezacaftor, 50 mg/die, Ivacaftor 75 mg/die) in combination with Ivacaftor (150 mg/die) as standard of care (Kaftrio + Kalydeco, Vertex Pharmaceuticals) in association with flunisolide (Fluspiral) 125 μg 1 puff × 2/day and salbutamol 3 puff × 2/day.

Techniques: Clinical Proteomics, Concentration Assay